OncoMatch/Clinical Trials/NCT05079282
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Is NCT05079282 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ONO-4685 for relapsed or refractory t cell lymphoma.
Treatment: ONO-4685 — This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II-B, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: anti-PD-1 therapy
Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L1 therapy
Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-CTLA-4 therapy
Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: checkpoint inhibitor (ONO-4685)
Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: CAR-T cell therapy
Prior allogeneic and autologous chimeric antigen receptor (CAR) T-cell therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- City of Hope · Duarte, California
- University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center · Orange, California
- Stanford Cancer Institute · Palo Alto, California
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify